Genetic health technology and economic evaluation: A critical review

Applied Health Economics and Health Policy

Volumn 5, Issue 1, 2006, Pages 27-35

  Jarrett, James ^a,b   Mugford, Miranda ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; GENE TECHNOLOGY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INFORMATION SERVICE; MEDICAL LITERATURE; MEDLINE; PUBLICATION; REVIEW;

BIOMEDICAL TECHNOLOGY; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; EVALUATION STUDIES; GENETICS; GREAT BRITAIN; HUMANS; STATE MEDICINE;

EID: 33745266377     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200605010-00004     Document Type: Review

References (48)

1. Raven A. Health economics and genetics literature. Cambridge, UK: Public Health Genetics Unit, 2001 Apr
2. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ: the BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83
3. Brain K, Gray J, Norman P, et al. Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst 2000; 92: 1345-51
4. Heckerling PS, Verp MS. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. Med Care 1994; 32: 863-80
5. Heimdal K, Maehle L, Moller P. Costs and benefits of diagnosing familial breast cancer. Dis Markers 1999; 15: 167-73
6. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4: 1-123
7. Venditti LN, Venditti CP, Berry GT, et al. Newborn screening by tandem mass spectrometry for medium-chain acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003; 112: 1005-15
8. Asch DA, Hershey JC, Dekay ML, et al. Carrier screening for cystic fibrosis: costs and clinical outcomes. Med Decis Making 1998; 18: 202-12
9. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999; 94: 1593-600
10. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology 1995 Dec; 22 (6): 1720-7
11. Braegger U. Cost-benefit, cost-effectiveness and cost-utility analyses of periodontitis prevention. J Clin Periodontol 2005 Oct; 32 Suppl. 6: 301-13
12. Brown ML, Kessler LG. Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Int J Cancer 1996 Feb 20; 69 (1): 55-7
13. Chikhaoui Y, Gelinas H, Joseph L, et al. Cost-minimization analysis of genetic testing versus clinical screening of at-risk relatives for familial adenomatous polyposis. Int J Technol Assess Health Care 2002; 18 (1): 67-80
14. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999 Oct; 72 (4): 646-51
15. Cuckle HS, Richardson GA, Sheldon TA, et al. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 1995 Dec 2; 311 (7018): 1460-3; discussion 1463-4
16. Cunningham GC, Tompkinison DG. Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1999; 1 (5): 199-206
17. DeVore GR. Is genetic ultrasound cost-effective? Semin Perinatol 2003 Apr; 27 (2): 173-82
18. El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients: a cost-effectiveness analysis. Ann Intern Med 2000 Feb 15; 132 (4): 261-9
19. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004 Mar 1; 22 (5): 854-63
20. Evans MI, Chik L, O'Brien JE, et al. MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. Am J Obstet Gynecol 1995 Apr; 172 (4 Pt 1): 1138-47; discussion 1147-9
21. Grann VR, Whang W, Jacobson JS, et al. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 1999 Feb; 17 (2): 494-500
22. Higashi MK, Veenstra DL, del Aguila M, et al. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. J Periodontol 2002 Dec; 73 (12): 1474-84
23. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004 Jun; 14 (6): 335-42
24. Kievit W, de Bruin JH, Adang EM, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005 Jan; 54 (1): 97-102
25. Lieu TA, Watson SE, Washington AE. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 1994 Dec; 84 (6): 903-12
26. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J 2002 Dec; 23 (24): 1922-30
27. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyl-transferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002 Dec; 29 (12): 2507-12
28. Modell B, Kuliev AM. Services for thalassaemia as a model for cost-benefit analysis of genetics services. J Inherit Metab Dis 1991; 14 (4): 640-51
29. Ramsey SD, Clarke L, Etzioni R, et al. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001 Oct 16; 135 (8 Pt 1): 577-88
30. Reyes CM, Allen BA, Terdiman JP, et al. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002 Nov 1; 95 (9): 1848-56
31. Rosenberg T, Jacobs HK, Thompson R, et al. Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy: how does this compare to existing neonatal screening for metabolic disorders? Soc Sci Med 1993 Aug; 37 (4): 541-7
32. Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet 1998 Oct; 63 (4): 1160-74
33. Sevilla C, Moatti JP, Julian-Reynier C, et al. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002 Oct; 10 (10): 599-606
34. Song FJ, Barton P, Sleightholme V, et al. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003; 7 (16): 1-106
35. van der Riet AA, van Hout BA, Rutten FF. Cost effectiveness of DNA diagnosis for four monogenic diseases. J Med Genet 1997 Sep; 34 (9): 741-5
36. Vasen HF, van Ballegooijen M, Buskens E, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998 May 1; 82 (9): 1632-7
37. Vintzileos AM, Ananth CV, Smulian JC, et al. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 1998 Apr; 91 (4): 529-34
38. Wildhagen MF, Hilderink HB, Verzijl JG, et al. Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health 1998 Jul; 52 (7): 459-67
39. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004 Feb; 4 (1): 97-104
40. Jarrett J, Mugford M. Review of economic evaluations of genetic diseases. Health Economics Group Research Report #18. 2006 [online]. Available from URL: http://www.uea.ac.uk/~wm085 [Accessed 2006 Mar 7]
41. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 2003; 5: 353-63
42. Mooney G, Lange M. Ante-natal screening: what constitutes 'benefit'? Soc Sci Med 1993 Oct; 37 (7): 873-8
43. Shackley P, Cairns J. Evaluating the benefits of antenatal screening: an alternative approach. Health Policy 1996 May; 36 (2): 103-15
44. Murray J, Cuckle H, Taylor G, et al. Screening for cystic fibrosis. Health Technol Assess 1999; 3: i-104
45. Nielsen R, Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002; 11: 285-99
46. Donaldson C, Shackley P, Abdalla M. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 1997 Mar-Apr 30; 6 (2): 145-59
47. Donaldson C. Eliciting patients' values by use of 'willingness to pay': letting the theory drive the method. Health Expect 2001 Sep; 4 (3): 180-8
48. Egger M, Juni P, Bartlett C, et al. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Health Technol Assess 2003; 7 (1): 1-7